The goal of this study is to determine if biomarkers can be used to be predictive of renal disease progression in diabetes as a method to enrich clinical trials with patients most at risk. From the SUMMIT (Surrogate Markers for Micro- and Macrovascular Hard Endpoints for Innovative Diabetes Tools) programme, the authors originally identified 207 serum biomarkers that is predictive of renal function decline. From these 207 biomarkers, the authors selected 42 biomarkers using forward selection and least absolute shrinkage and selection operator (LASSO) penalized regression approaches. The 42 biomarkers were split into smaller panels and tested for the ability to predict performance similar to the larger panels.
Timothy Garvey, Luc Van Gaal, Lawrence A. Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J. Davies
Metabolism. 2018. doi: 10.1016/j.metabol.2018.02.002
Type 2 diabetic patients with increased visceral fat mass and insulin resistance are at a higher risk for cardiovascular disease and premature death. The increased visceral fat impairs adipose tissue function and is the result of combinatorial processes, including increased macrophage recruitment (MCP-1 production), increased inflammatory cytokines (IL-6 and TNF-a secretion), and reduced anti-inflammatory factors (adipokine and adiponectin).
Novel nonglycemic biomarker for metformin
The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial delivers more insight on biomarkers that have potential to help treat patients with dysglycemia.1 Hertzel C. Gerstein and colleagues report Growth Differentiation Factor 15 (GDF15) as a novel biomarker for the use and dosing of metformin, in a study published in Diabetes Care last month.
An international team of researchers used Myriad RBM’s Multi-Analyte Profile (MAP) technology to identify a pattern of cardiometabolic biomarkers that appears to predict cardiovascular outcomes in patients with dysglycemia. This data, the latest publication stemming from the landmark Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, holds great promise for prognosis and treatment of patients suffering from diseases caused by abnormalities in blood glucose levels.
The epidemic of obesity in America is staggering and the costs of treating the diseases associated with being overweight are increasing. The prevalence of pediatric Type-2 diabetes (T2D) is particularly troubling since there has been a marked increase in frequency. Early intervention can reverse or prevent some of the more serious side-effects of the disease but detection is critical. Here the researchers describe a study using a non-invasive collection of saliva and test for metabolic-related biomarker differences in children with T2D. https://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0098799
As a major participant in the largest protein biomarker study of its kind, Myriad RBM will analyze more than 8,000 samples for Sanofi Aventis’ Outcome Reduction with Initial Glargine Intervention (ORIGIN) project, a pre- and early diabetes clinical study. The goal of the collaboration is to identify biomarker profiles that optimize treatment and improve care for diabetes patients. The research will be done using an expanded version of Myriad RBM’s DiscoveryMAP service and will provide quantitative measurement of nearly 300 blood-based proteins. The Population Health Research Institute (PHRI) managed the ORIGIN trial and is contributing samples and guiding data analysis to link biomarker measurements to clinical outcomes.